Global Information
회사소개 | 문의 | 위시리스트

염증성 장질환(IBD) : 기회 평가, 역학 예측, 시장 역학, 파이프라인 분석

Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

리서치사 GervanoRA Data Services LLP
발행일 2019년 03월 상품 코드 769583
페이지 정보 영문 250 Pages
가격
US $ 2,500 ₩ 3,012,000 PDF by E-mail (General License)


염증성 장질환(IBD) : 기회 평가, 역학 예측, 시장 역학, 파이프라인 분석 Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018
발행일 : 2019년 03월 페이지 정보 : 영문 250 Pages

세계의 염증성 장질환(IBD : Inflammatory Bowel Diseases) 치료제 시장에 대해 조사 분석했으며, 현재 및 향후의 기회에 초점을 맞추어 시장 가치, 특허 분석, 시장 점유율 등에 대한 체계적인 정보를 제공합니다.

제1장 서론

제2장 주요 요약

제3장 질환 개요

  • 질환 정의와 증상
  • 병인과 분류
  • 질환 진단
  • 치료 알고리즘과 가이드라인
  • 역학과 질병 부담
  • 역학 예측

제4장 시장 역학

  • 정부 규제 동향과 영향
  • 가격과 상환
  • 거래(M&A, 제휴)
  • 신약 승인(미국 FDA)
  • 신약 승인(EMA)
  • 특허 분석(만료, 제네릭 의약품)

제5장 파이프라인 분석

  • 파이프라인 분석 : 개발 단계별
  • 파이프라인 분석 : 지역별
  • 파이프라인 분석 : 투여 경로별
  • 파이프라인 분석 : 약제 분류별
  • 파이프라인 분석 : 작용기서별
  • 파이프라인 분석 : 대학 및 기관별

제6장 승인 스케줄 예측

제7장 염증성 장질환(IBD) 치료제 임상시험 요약

  • 염증성 장질환(IBD) 치료제 파이프라인 분석 : 임상시험 결과별
  • 진행중인 임상시험 요약
  • 계획중인 임상시험 요약
  • 최근 완료된 임상시험 요약

제8장 현재 및 향후 경쟁 상황

  • 기업
  • 대학 및 기관

제9장 약어

KSM 19.01.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

GervanoRA's pipeline analysis and opportunity assessment report "Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018" analyzed and assessed Inflammatory Bowel Diseases pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Inflammatory Bowel Diseases industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2028
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT MAJOR FINDINGS
  • 2.2. KEY PIPELINE EVENTS (REGULATORY APPROVALS), 2019-2029

3. DISEASE OVERVIEW

  • 3.1. DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHMS AND GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET OVERVIEW

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
  • 4.2. NEW DRUG APPROVALS (EMA) SINCE 2010
  • 4.3. NEW DRUG APPROVALS (US FDA) SINCE 2010

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
    • 5.1.7. INACTIVE AND DISCONTINUED MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES
    • 5.6.1. PIPELINE MOLECULES DEVELOPING BY COMPANIES
    • 5.6.2. PIPELINE MOLECULES DEVELOPING BY UNIVERSITIES

6. ESTIMATED APPROVAL TIMELINES

  • 6.1. METHODOLOGY
  • 6.2. ESTIMATED APPROVAL TIMELINES US & EX-US

7. CLINICAL TRIAL SUMMARY

  • 7.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
  • 7.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
  • 7.3. ONGOING CLINICAL TRIALS SUMMARY
    • 7.3.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 7.3.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 7.3.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 7.4. PLANNED CLINICAL TRIALS SUMMARY
    • 7.4.1. PLANNED PHASE 2 CLINICAL TRIALS
    • 7.4.2. PLANNED PHASE 1 CLINICAL TRIALS
  • 7.5. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 7.5.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS (2013-2018)
    • 7.5.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS (2013-2018)
    • 7.5.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS (2013-2018)

8. WITHDRAWN AND TERMINATED PROJECTS

  • 8.1. WITHDRAWN CLINICAL TRIALS
  • 8.2. TERMINATED CLINICAL TRIALS

9. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 9.1. ESTABLISHED COMPANIES
  • 9.2. ESTABLISHED COMPANY PROFILES AND SWOT ANALYSIS
    • 9.2.1. ABBVIE INC.
    • 9.2.2. JOHNSON & JOHNSON, INC
    • 9.2.3. AMGEN INC
    • 9.2.4. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 9.2.5. PFIZER PHARMACEUTICALS
  • 9.3. EMERGING COMPANIES
  • 9.4. KEY EMERGING COMPANY PROFILES
    • 9.4.1. INNOVATE BIOPHARMACEUTICALS, INC
    • 9.4.2. AEVI GENOMIC MEDICINE INC
    • 9.4.3. ABGENOMICS INTERNATIONAL INC.
    • 9.4.4. PROVENTION BIO, INC
    • 9.4.5. LIPID THERAPEUTICS GMBH
    • 9.4.6. STERNA BIOLOGICALS
    • 9.4.7. ABIVAX S.A.
    • 9.4.8. AERPIO PHARMACEUTICALS INC.
    • 9.4.9. ARENA PHARMACEUTICALS, INC.
    • 9.4.10. CONNECT BIOPHARMACEUTICALS LTD.
  • 9.5. UNIVERSITIES AND INSTITUTES

10. ABBREVIATIONS

LIST OF TABLES:

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: LOCATION BASED DISEASE CLASSIFICATION
  • TABLE 03: BEHAVIOURAL BASED DISEASE CLASSIFICATION
  • TABLE 04: INTERNATIONAL DEFINITIONS FOR CROHN'S DISEASE BY AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG)
  • TABLE 05: INTERNATIONAL DEFINITIONS FOR CROHN'S DISEASE BY EUROPEAN CROHN'S AND COLITIS ORGANISATION (ECCO)
  • TABLE 06: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG)
  • TABLE 07: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY EUROPEAN CROHN'S AND COLITIS ORGANISATION (ECCO)
  • TABLE 08: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY JAPANESE SOCIETY OF GASTROENTEROLOGY
  • TABLE 09: IBD EPIDEMIOLOGY (2016), FORECAST (2017-2028)
  • TABLE 10: MAJOR ACQUISITIONS AND MERGERS IN IBD THERAPEUTIC AREA SINCE 2012
  • TABLE 11: MAJOR COLLABORATIVE AGREEMENTS IN IBD THERAPEUTIC AREA
  • TABLE 12: MAJOR LICENSING AGREEMENTS IN IBD THERAPEUTIC AREA
  • TABLE 13: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN IBD THERAPEUTIC AREA
  • TABLE 14: EMA APPROVED DRUGS SINCE 2010
  • TABLE 15: EMA APPROVED BIOSIMILARS SINCE 2010
  • TABLE 16: US FDA APPROVED DRUGS SINCE 2010
  • TABLE 17: US FDA APPROVED BIOSIMILARS SINCE 2010
  • TABLE 18: COMPANY PIPELINE MOLECULES BY PHASE OF DEVELOPMENT
  • TABLE 19: IBD PRE-REGISTRATION STAGE CANDIDATES
  • TABLE 20: PHASE 3 PIPELINE MOLECULES
  • TABLE 21: PHASE 2 PIPELINE MOLECULES
  • TABLE 22: PHASE 1 PIPELINE MOLECULES
  • TABLE 23: PRECLINICAL STAGE PIPELINE MOLECULES
  • TABLE 24: EARLY R&D PIPELINE MOLECULES
  • TABLE 25: INACTIVE AND DISCONTINUED MOLECULES
  • TABLE 26: IBD DRUG PIPELINE BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 27: IBD DRUG PIPELINE BY INJECTABLE AS ROUTE OF ADMINISTRATION
  • TABLE 28: IBD DRUG PIPELINE, IMMUNOMODULATORS
  • TABLE 29: IBD DRUG PIPELINE, ANTI-INFLAMMATORY
  • TABLE 30: MOLECULES DEVELOPED BY COMPANIES
  • TABLE 31: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
  • TABLE 32: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 33: TOFACITINIB PHASE 3 CLINICAL TRIALS STUDY DESIGN
  • TABLE 34: USTEKINUMAB PHASE 3 CLINICAL TRIALS STUDY DESIGN
  • TABLE 35: UPADACITINIB (ABT-494) PHASE 2 CLINICAL TRIALS STUDY DESIGN
  • TABLE 36: RESULTS FROM 52-WEEK CELEST STUDY, UPADACITINIB (ABT-494)-ABBVIE
  • TABLE 37: APREMILAST (OTEZLA) PHASE 2 CLINICAL TRIALS STUDY DESIGN
  • TABLE 38: MIRIKIZUMAB (LY3074828) PHASE 2 CLINICAL TRIALS STUDY DESIGN
  • TABLE 39: RESULTS FROM 12- WEEK STUDY, MIRIKIZUMAB (LY3074828) - ELI LILLY AND COMPANY
  • TABLE 40: PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 41: PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 42: PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 43: PLANNED PHASE 2 CLINICAL TRIALS FOR IBD
  • TABLE 44: PLANNED PHASE 1 CLINICAL TRIALS FOR IBD
  • TABLE 45: RECENTLY COMPLETED PHASE 3 TRIALS (2013-2018)
  • TABLE 46: RECENTLY COMPLETED PHASE 2 TRIALS (2013-2018)
  • TABLE 47: RECENTLY COMPLETED PHASE 1 TRIALS (2013-2018)
  • TABLE 48: WITHDRAWN CLINICAL TRIALS FOR IBD
  • TABLE 49: TERMINATED CLINICAL TRIALS FOR IBD
  • TABLE 50: MARKETED PRODUCTS OF ABBVIE INC.
  • TABLE 51: IMMUNOLOGY PIPELINE PRODUCTS OF ABBVIE INC.
  • TABLE 52: ONCOLOGY PIPELINE PRODUCTS OF ABBVIE INC.
  • TABLE 53: NEUROSCIENCE PIPELINE PRODUCTS OF ABBVIE INC.
  • TABLE 54: R&D ACTIVITIES OF ABBVIE INC.
  • TABLE 55: ACHIEVED MILESTONES BY ABBVIE INC.
  • TABLE 56: ANTICIPATED MILESTONES BY ABBVIE INC.
  • TABLE 57: PRESENTATIONS\CONFERENCES\EVENTS BY ABBVIE INC.
  • TABLE 58: RECENT DEVELOPMENTS BY ABBVIE INC.
  • TABLE 59: MARKETED PRODUCTS OF J&J
  • TABLE 60: J&J PIPELINE PRODUCTS
  • TABLE 61: R&D ACTIVITIES OF J&J
  • TABLE 62: ACHIEVED MILESTONES BY J&J
  • TABLE 63: PLANNED POTENTIAL APPROVALS IN US AND EU IN 2019
  • TABLE 64: PLANNED POTENTIAL APPROVALS IN US AND EU IN 2019
  • TABLE 65: PRESENTATIONS/EVENTS/CONFERENCES ATTENDED BY J&J
  • TABLE 66: RECENT DEVELOPMENTS BY J&J
  • TABLE 67: MARKETED PRODUCTS OF AMGEN
  • TABLE 68: AMGEN PIPELINE PRODUCTS
  • TABLE 69: R&D ACTIVITIES OF AMGEN INC.
  • TABLE 70: ACHIEVED MILESTONES BY AMGEN INC.
  • TABLE 71: PRESENTATIONS/EVENTS/CONFERENCES ATTENDED BY AMGEN
  • TABLE 72: RECENT DEVELOPMENTS BY AMGEN
  • TABLE 73: ANNUAL REVENUES OF KEY PRODUCTS FOR THE YEAR ENDED MARCH 2018($BN)
  • TABLE 74: TAKEDA PIPELINE PRODUCTS
  • TABLE 75: R&D ACTIVITIES OF TAKEDA
  • TABLE 76: ACHIEVED MILESTONES BY TAKEDA
  • TABLE 77: PRESENTATIONS/EVENTS/CONFERENCES ATTENDED BY TAKEDA
  • TABLE 78: RECENT DEVELOPMENTS BY TAKEDA
  • TABLE 79: PFIZER PRODUCT PORTFOLIO
  • TABLE 80: INFLAMMATION AND IMMUNOLOGY AREA PRODUCT PIPELINE
  • TABLE 81: PHASE 2 AND PHASE 1 PROGRAM, INTERNAL MEDICINE
  • TABLE 82: ONCOLOGY THERAPY AREA PRODUCT PIPELINE
  • TABLE 83: PRODUCTS UNDER DEVELOPMENT, RARE DISEASES
  • TABLE 84: VACCINES UNDER DEVELOPMENT
  • TABLE 85: R&D ACTIVITIES OF PFIZER
  • TABLE 86: ACHIEVED MILESTONES BY PFIZER
  • TABLE 87: CONFERENCES/EVENTS ATTENDED BY PFIZER
  • TABLE 88: RECENT DEVELOPMENTS MADE BY PFIZER
  • TABLE 89: INNOVATE BIOPHARMACEUTICALS PIPELINE MOLECULES
  • TABLE 90: RECENT DEVELOPMENT MILESTONES ACHIEVED BY INNOVATE BIOPHARMACEUTICAL
  • TABLE 91: ANTICIPATED MILESTONES OF INNOVATE BIOPHARMACEUTICALS
  • TABLE 92: PRESENTATIONS/CONFERENCES/EVENTS BY INNOVATE BIOPHARMACEUTICALS
  • TABLE 93: AEVI GENOMIC MEDICINE, INC PIPELINE MOLECULES
  • TABLE 94: R&D ACTIVITIES BY AEVI GENOMIC MEDICINE
  • TABLE 95: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY AEVI GENOMIC MEDICINE
  • TABLE 96: RECENT DEVELOPMENTS OF AEVI GENOMIC MEDICINE
  • TABLE 97: ABGENOMICS INTERNATIONAL INC. PIPELINE MOLECULES
  • TABLE 98: U.S PATENTS OF ABGENOMICS INTERNATIONAL INC.
  • TABLE 99: DEVELOPMENT MILESTONES OF ABGENOMICS INTERNATIONAL INC.
  • TABLE 100: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY ABGENOMICS INTERNATIONAL INC.
  • TABLE 101: PIPELINE PRODUCTS OF PROVENTION BIO
  • TABLE 102: ANTICIPATED MILESTONES OF PROVENTION BIO
  • TABLE 103: RECENT DEVELOPMENTS OF PROVENTION BIO
  • TABLE 104: R&D ACTIVITIES CARRIED OUT BY LIPID THERAPEUTICS GMBH
  • TABLE 105: PIPELINE PRODUCTS OF STERNA BIOLOGICALS
  • TABLE 106: PATENTS ISSUED TO STERNA BIOLOGICALS
  • TABLE 107: R&D ACTIVITIES CARRIED OUT BY STERNA BIOLOGICALS
  • TABLE 108: PRESENTATIONS/CONFERENCES/EVENTS BY STERNA BIOLOGICALS
  • TABLE 109: RECENT DEVELOPMENTS BY STERNA BIOLOGICALS
  • TABLE 110: ABIVAX S.A. PIPELINE MOLECULES
  • TABLE 111: PATENTS OF ABIVAX S.A.
  • TABLE 112: PATENTS STATUS OF ABIVAX S.A.
  • TABLE 113: R&D ACTIVITIES BY ABIVAX S.A.
  • TABLE 114: ANTICIPATED MILESTONES OF ABIVAX S.A.
  • TABLE 115: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY ABIVAX S.A.
  • TABLE 116: RECENT DEVELOPMENTS BY ABIVAX S.A.
  • TABLE 117: PIPELINE PRODUCTS OF AERPIO PHARMACEUTICALS
  • TABLE 118: R&D ACTIVITIES CARRIED OUT BY AERPIO PHARMACEUTICALS
  • TABLE 119: ANTICIPATED MILESTONES FOR AERPIO PHARMACEUTICALS
  • TABLE 120: PRESENTATIONS/CONFERENCES/EVENTS BY AERPIO PHARMACEUTICALS
  • TABLE 121: RECENT DEVELOPMENTS OF AERPIO PHARMACEUTICALS
  • TABLE 122: PIPELINE MOLECULES OF ARENA PHARMACEUTICALS, INC.
  • TABLE 123: R&D ACTIVITIES OF ARENA PHARMACEUTICALS, INC.
  • TABLE 124: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY ARENA PHARMACEUTICALS, INC.
  • TABLE 125: RECENT DEVELOPMENTS BY ARENA PHARMACEUTICALS, INC.
  • TABLE 126: PIPELINE MOLECULES OF CONNECT BIOPHARMACEUTICALS
  • TABLE 127: RECENT DEVELOPMENT MILESTONES OF CONNECT BIOPHARMACEUTICALS
  • TABLE 128: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY CONNECT BIOPHARMACEUTICALS
  • TABLE 129: LIST OF UNIVERSITIES AND INSTITUTES

LIST OF FIGURES:

  • FIGURE 01: KEY PIPELINE EVENTS BY HIGHEST STAGE OF DEVELOPMENT
  • FIGURE 02: US IBD EPIDEMIOLOGY (2016), FORECAST (2017-2028)
  • FIGURE 03: OVERALL DEALS ACTIVITY IN IBD THERAPEUTIC AREA
  • FIGURE 04: COMPANIES WITH NUMBER OF DEALS
  • FIGURE 05: PIPELINE MOLECULES MIX FOR IBD
  • FIGURE 06: IBD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 07: IBD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINSTRATION
  • FIGURE 08: REMISSION RATES AT WEEK 52 (IN PERCENT)
  • FIGURE 09: MUCOSAL HEALING AT WEEK 52 (IN PERCENT)
  • FIGURE 10: SUSTAINED STEROID-FREE REMISSION AT WEEK 52 (IN PERCENT)
  • FIGURE 11: OVERALL INFECTION RATES AT WEEK 52 (IN PERCENT)
  • FIGURE 12: CLINICAL REMISSION RATES (IN %) AT WEEK 8
  • FIGURE 13: ENDOSCOPIC HEALING RATES (IN %) AT WEEK 8
  • FIGURE 14: CLINICAL RESPONSE RATES (IN %) AT WEEK 8
  • FIGURE 15: ABBVIE INC. REVENUES, 2017 VS. 2018 (IN $ MILLIONS)
  • FIGURE 16: ABBVIE INC. REVENUES FOR FOURTH QUARTER 2017 VS. 2018 (IN $ MILLIONS)
  • FIGURE 17: ABBVIE INC. REVENUES GEOGRAPHICALLY IN 2018 (IN %)
  • FIGURE 18: ABBVIE INC. REVENUES COMPARISON OF MAJOR BUSINESS SEGMENTS
  • FIGURE 19: ABBVIE INC. REVENUES BY THERAPEUTIC AREA IN U.S MARKET (IN $ M)
  • FIGURE 20: SWOT ANALYSIS OF ABBVIE
  • FIGURE 21: J&J ANNUAL REVENUES (IN $M)
  • FIGURE 22: J&J ANNUAL R&D EXPENSES (IN $M)
  • FIGURE 23: J&J SALES BY BUSINESS SEGMENTS
  • FIGURE 24: J&J ANNUAL REVENUES SPLIT BY GEOGRAPHIES
  • FIGURE 25: ANNUAL PHARMACEUTICAL SEGMENT REVENUES COMPARISON
  • FIGURE 26: MAJOR PHARMACEUTICAL THERAPEUTIC AREA SALES
  • FIGURE 27: SWOT ANALYSIS OF J&J
  • FIGURE 28: AMGEN TOTAL REVENUES (IN $M)
  • FIGURE 29: AMGEN TOTAL PRODUCT SALES COMPARISON (IN $M), 2017 V/S 2018
  • FIGURE 30: AMGEN MAJOR PRODUCTS SHARE IN TOTAL PRODUCT SALES, 2018
  • FIGURE 31: AMGEN R&D EXPENSE BY CATEGORY
  • FIGURE 32: SWOT ANALYSIS OF AMGEN
  • FIGURE 33: TAKEDA ANNUAL REVENUES (IN $ BN)
  • FIGURE 34: TAKEDA TOTAL REVENUES BY GEOGRAPHY
  • FIGURE 35: SWOT ANALYSIS OF TAKEDA
  • FIGURE 36: PFIZER ANNUAL REVENUES (IN $ BN)
  • FIGURE 37: PFIZER SALES BY BUSINESS SEGMENT, 2018
  • FIGURE 38: PFIZER ANNUAL SALES SPLIT BY GEOGRAPHY, 2018
  • FIGURE 39: THERAPEUTIC SHARE IN INNOVATIVE HEALTH SEGMENT, 2018
  • FIGURE 40: SWOT ANALYSIS OF PFIZER
Back to Top
전화 문의
F A Q
 
BCC Research